IFM Investors Pty Ltd bought a new position in shares of Align Technology, Inc. (NASDAQ:ALGN) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 2,154 shares of the medical equipment provider’s stock, valued at approximately $401,000.

Several other hedge funds have also bought and sold shares of the stock. Buckingham Asset Management LLC increased its holdings in shares of Align Technology by 3.3% during the 2nd quarter. Buckingham Asset Management LLC now owns 1,861 shares of the medical equipment provider’s stock worth $279,000 after acquiring an additional 59 shares during the last quarter. BB&T Securities LLC increased its holdings in shares of Align Technology by 3.5% during the 2nd quarter. BB&T Securities LLC now owns 2,757 shares of the medical equipment provider’s stock worth $413,000 after acquiring an additional 94 shares during the last quarter. Wesbanco Bank Inc. boosted its stake in Align Technology by 0.9% in the 2nd quarter. Wesbanco Bank Inc. now owns 11,054 shares of the medical equipment provider’s stock valued at $1,659,000 after purchasing an additional 100 shares during the period. Bronfman E.L. Rothschild L.P. boosted its stake in Align Technology by 13.0% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 912 shares of the medical equipment provider’s stock valued at $137,000 after purchasing an additional 105 shares during the period. Finally, Commonwealth Bank of Australia boosted its stake in Align Technology by 10.5% in the 2nd quarter. Commonwealth Bank of Australia now owns 1,129 shares of the medical equipment provider’s stock valued at $169,000 after purchasing an additional 107 shares during the period. 84.04% of the stock is currently owned by institutional investors and hedge funds.

ALGN has been the subject of several recent research reports. Leerink Swann restated an “outperform” rating and issued a $250.00 price target on shares of Align Technology in a research note on Friday, October 27th. Morgan Stanley boosted their price target on Align Technology from $257.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, November 27th. Zacks Investment Research upgraded Align Technology from a “hold” rating to a “buy” rating and set a $227.00 price target for the company in a research note on Monday, October 30th. Credit Suisse Group boosted their price target on Align Technology from $175.00 to $209.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Finally, Northcoast Research restated a “buy” rating and issued a $230.00 price target (up from $200.00) on shares of Align Technology in a research note on Tuesday, October 10th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $236.75.

Shares of Align Technology, Inc. (NASDAQ:ALGN) opened at $233.55 on Friday. The firm has a market capitalization of $18,710.00, a price-to-earnings ratio of 69.17, a PEG ratio of 2.23 and a beta of 1.43. Align Technology, Inc. has a 1 year low of $88.56 and a 1 year high of $266.41.

Align Technology (NASDAQ:ALGN) last released its earnings results on Thursday, October 26th. The medical equipment provider reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.19. The firm had revenue of $385.30 million during the quarter, compared to the consensus estimate of $359.80 million. Align Technology had a return on equity of 25.60% and a net margin of 19.98%. The company’s revenue was up 38.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.63 EPS. equities analysts expect that Align Technology, Inc. will post 3.62 EPS for the current year.

In other news, Director Greg J. Santora sold 7,700 shares of the company’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $238.95, for a total transaction of $1,839,915.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joseph Lacob sold 29,724 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $260.91, for a total value of $7,755,288.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 52,849 shares of company stock valued at $13,494,348. Corporate insiders own 1.60% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “IFM Investors Pty Ltd Buys New Holdings in Align Technology, Inc. (ALGN)” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/ifm-investors-pty-ltd-buys-new-holdings-in-align-technology-inc-algn/1769045.html.

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Institutional Ownership by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with Analyst Ratings Network's FREE daily email newsletter.